Estar Medical's patented platform method produces autologous platelet-rich plasma and other related cell therapy technologies for human use. This platform technology, distributed under the registered trademarks of Tropocells and Cellenis, processes the patient's own blood for the purpose of using the platelets, cells, and essential proteins for indications in various medical disciplines such as dermatology, aesthetics, orthopedics, sports medicine, wound care, pain management, dental, ophthalmology, and veterinary. Estar Medical's products can be applied either on a standalone basis or to complement other biological and therapeutic methods. The Tropocells and Cellenis product portfolio is based on a proprietary patented technology which is US FDA cleared for orthopedic applications, CE certified (Class IIb), and ISO 13485 approved working under strict GMP standards.